AceVision

What in the ophthalmic field is your team most excited about right now?

 

AVG is excited about the future growth potential for the presbyopia category. Therapeutic solutions are on the horizon, and Laser Scleral Microporation (LSM) is a viable vision and aesthetic treatment performed with the first-in-class VisioLite® Ophthalmic Laser.

 

In what area of ophthalmology do you think your team can make an extraordinary impact?

 

AVG provides a therapeutic solution to help patients see clearly and naturally during their presbyopic lifespan. LSM is an in-office, non-invasive procedure that offers a therapeutic solution to treat functional loss of vision, resolving agerelated vision disability and potentially preventing the age-related progression of presbyopia.

 

What are the biggest challenges when making an impact with new technology or innovations?

 

Educating the clinical community about the biomechanics of the eye and how aging affects the dynamic movement inside the eye or the Dynamic Range of Focus (DRoF) function is challenging and not typically taught in the ophthalmology curriculum. Furthering presbyopia education will require a paradigm shift from approaching it as a ‘refractive error’ with a vision correction solution to an aging disease, which involves a therapeutic intervention to treat the disease’s progression over time. LSM is a rejuvenating procedure that treats agerelated ocular rigidity by “uncrosslinking” collagen bonds making the tissue flexible again. LSM is extraocular, touching no optics, yet creating an impact on restoring the ability for the muscles to change the shape of the natural crystalline lens, giving patients back youthful vision naturally.

 

What does pursuing excellence look like for your team?

 

Pursuing excellence means making a significant positive impact on eye care for millions of patients worldwide. We are trailblazing an untrodden path and creating a new category of vision therapy with our VisioLite® device and LSM Treatment. Our technology and procedures are evidence-based and backed by deep scientific rigor. We expect to benefit patients and the industry with our new exciting innovations.

 

Who are the role models in the community that model excellence in their work?

 

AVG has been fortunate to have the most elite mentors in ophthalmology. It is inspiring to witness those who have boldly forged ahead with new science and built organizations in the face of adversity. Professor John Marshall, inventor of excimer laser technology for refractive surgery, has been instrumental in helping us forge this new ophthalmic technology. Marsha Link, CEO coach, has inspired and mentored many CEOs through the entrepreneurial adventure, providing invaluable advice and leadership. Finally, Dr. Dan Neal, a visionary in optics, has contributed so much knowledge and technology in the dynamic measurement of vision in presbyopia.